An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 3, 2014, Pages 188-193

  Szabatura, Audrea H ^a   Cirrone, Frank ^b   Harris, Christy ^c   McDonnell, Anne M ^d   Feng, Yang ^a   Voit, Daniel ^d   Neuberg, Donna ^a   Butrynski, James ^a   Fisher, David C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aprepitant; CYP3A4 and CYP2B6 inhibitors; drug interactions; encephalopathy; Ifosfamide; risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; CYTOCHROME P450 2B6 INHIBITOR; HEMOGLOBIN; IFOSFAMIDE; OPIATE; UREA; ALKYLATING AGENT;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CANCER CENTER; CANCER CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IFOSFAMIDE INDUCED ENCEPHALOPATHY; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; CHEMICALLY INDUCED; MIDDLE AGED; NEUROTOXICITY SYNDROMES;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN DISEASES; CANCER CARE FACILITIES; CISPLATIN; FEMALE; HUMANS; IFOSFAMIDE; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA;

EID: 84930424829     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214527143     Document Type: Article

References (25)

1. Howell JE, Szabatura AH, Seung AH, et al. Characterization of the occurrence of ifosfamide-induced encephalopathy with concomitant aprepitant. J Oncol Pharm Practice. 2008 ; 14: 157-162
2. Jarkowski A, Miller A, Hecke TA, et al. The risk of neurotoxicity with concomitant use of aprepitant and ifosfamide. J Hematol Oncol Pharm. 2011 ; 1: 16-21
3. Patel PN. Methylene blue for ifosfamide-induced encephalopathy. Ann Pharmacother. 2006 ; 40: 299-303
4. Ajithkumar T, Parkinson C, Shamshad F, et al. Ifosfamide encephalopathy. Clin Oncol. 2007 ; 19: 108-114
5. Giovanis P, Garna A, Marcante M, et al. Ifosfamide encephalopathy and use of methylene blue: a case report of different sequential neurotoxicity. Tumori. 2009 ; 95: 545-546
6. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003 ; 65: 11-16
7. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005 ; 28: 277-280
8. Brunello A, Basso U, Rossi E, et al. Ifosfamide-related encephalopathy in elderly patients: report of five cases and review of the literature. Drugs Aging. 2007 ; 24: 967-973
9. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006 ; 12: 237-239
10. Buesa JM, Garcia-Teijido P, Losa R, et al. Treatment of ifosfamide encephalopathy with intravenous thiamine. Clin Cancer Res. 2003 ; 9: 4636-4637
11. Park IS, Lee HJ, Lee YS, et al. Ifosfamide-induced encephalopathy with or without using methylene blue. Int J Gynecol Cancer. 2005 ; 15: 807-810
12. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000 ; 82: 291-294
13. Richards A, Marshall H, McQuary A. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract. 2011 ; 17: 372-380
14. Kettle JK, Grauer D, Folker TL, et al. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacother. 2010 ; 30: 812-817
15. Lombardi G, Zustovich MO, Donach M, et al. Letter to the editor. J Oncol Pharm Pract. 2010 ; 16: 135-136
16. Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007 ; 12: 1351-1360
17. Bruggemann SK, Pfaffle S, Peters SO, et al. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab Dispos. 2007 ; 35: 1721-1724
18. Ho H, Yuen C. [Letter to the editor]. J Oncol Pharm Pract. 2010 ; 16: 137-138
19. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000 ; 59: 961-972
20. Meanwell CA, Blake AE, Kelly KA, et al. Predication of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986 ; 22: 815-819
21. Wheeler BM, Loehrer PJ, Williams SD, et al. Ifosfamide in refractory male germ cell tumors. J Clin Oncol. 1986 ; 4: 28-34
22. Niederle N, Scheulen ME, Cremer M, et al. Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev. 1983 ; 10: 129-135
23. Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy. Cancer Res. 1987 ; 47: 1457-1460
24. Sweiss KI, Beri R, Shord SS. Encephalopathy after high-dose ifosfamide: a retrospective cohort study and review of the literature. Drug Safety. 2008 ; 31: 989-996
25. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet. 2000 ; 38: 291-304